{"id":"NCT02414958","sponsor":"Boehringer Ingelheim","briefTitle":"Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)","officialTitle":"A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to inSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06-30","primaryCompletion":"2017-04-20","completion":"2017-10-23","firstPosted":"2015-04-13","resultsPosted":"2018-11-20","lastUpdate":"2019-01-03"},"enrollment":730,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"Empagliflozin","otherNames":[]},{"type":"DRUG","name":"Empagliflozin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Empagliflozin low dose","type":"EXPERIMENTAL"},{"label":"Empagliflozin high dose","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Comparison of 2 doses of empagliflozin vs placebo in patients already using either an insulin regimen of multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). Randomisation to 3 treatments arms (equal assignment) following a screening period, an optimisation period and a run-in period. 52 week double-blind treatment period, and 3 week follow-up period.","primaryOutcome":{"measure":"Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26","timeFrame":"Baseline to week 26","effectByArm":[{"arm":"Placebo Matching Empagliflozin","deltaMin":0.09,"sd":0.04},{"arm":"Empagliflozin 10 mg","deltaMin":-0.44,"sd":0.04},{"arm":"Empagliflozin 25 mg","deltaMin":-0.44,"sd":0.04}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":131,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Netherlands","Norway","Poland","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["37616393","30287422"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":243},"commonTop":["Hypoglycaemia","Nasopharyngitis","Urinary tract infection","Upper respiratory tract infection","Blood ketone body increased"]}}